Tempus AI Inc., a prominent player in the healthcare sector, has recently filed a Rule 144 disclosure with the U.S. Securities and Exchange Commission (SEC), providing transparency into its recent equity transactions. This filing is a critical development for stakeholders, as it outlines the sale of Class A common shares by the company on the Nasdaq exchange.
The disclosure reveals that Tempus AI Inc. executed several transactions in February and March 2026, culminating in the sale of 133,000 shares on March 26, 2026. These transactions are part of the company’s broader strategy to manage its public-equity profile. The filing meticulously details the number of shares sold, the gross proceeds from these sales, and identifies the sellers involved, ensuring compliance with regulatory requirements and maintaining transparency with investors.
As of April 28, 2026, Tempus AI Inc.’s shares were trading at a close price of $50.02. This figure is notably above the 52-week low of $41.73, recorded on March 29, 2026, but still significantly below the 52-week high of $104.32, achieved on October 8, 2025. The company’s market capitalization stands at approximately $9.16 billion, reflecting its substantial presence in the healthcare sector.
A notable aspect of Tempus AI Inc.’s financial metrics is its price-to-earnings (P/E) ratio, which is currently at -40.12. This negative P/E ratio indicates that the company is not currently generating positive earnings, a factor that investors must consider when evaluating the company’s financial health and future prospects.
The Rule 144 filing does not disclose any other material corporate actions or financial results, suggesting that the company is focusing on its equity transactions without any immediate changes in its operational or financial strategies. This approach may be indicative of a strategic pause, allowing the company to stabilize its financial standing before pursuing further growth initiatives.
In summary, Tempus AI Inc.’s recent SEC filing provides valuable insights into its equity transactions, reflecting a strategic approach to managing its public-equity profile amidst a challenging financial landscape. As the company navigates its current market position, stakeholders will be keenly observing its future moves, particularly in light of its negative P/E ratio and the broader dynamics within the healthcare sector.
